Patents Assigned to Centre de Recherche du Chul
  • Linked breast and ovarian cancer susceptibility gene
    Patent number: 5709999
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignees: Myriad Genetics Inc., Centre de Recherche du Chul, Cancer Institute
    Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura
  • Linked breast and ovarian cancer susceptibility gene
    Patent number: 5693473
    Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignees: Myriad Genetics, Inc., Centre de Recherche du Chul, Cancer Institute
    Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura